Clinical Trials Logo

Filter by:
NCT ID: NCT04684264 Completed - Heart Failure Clinical Trials

Feasibility of the Implementation of Tools for Heart Failure Risk Prediction

FIT-HF
Start date: March 3, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to gather information to develop a heart failure screening and prevention program.

NCT ID: NCT04684199 Completed - Dyspepsia Clinical Trials

Melatonin in Pediatric FD Population

Start date: August 2014
Phase: N/A
Study type: Interventional

There are two specific aims in this study. Specific Aim 1: Determine if melatonin results in a higher grade of clinical response than does placebo in children with functional dyspepsia (FD). Hypothesis: treatment of FD with melatonin will result in a higher grade of clinical response than will treatment with a placebo. Specific Aim 2: Evaluate the relationship between changes in sleep and improvement in pain in pediatric patients with functional dyspepsia receiving melatonin. Hypothesis: There will be no association between improvement in pain and improvement in sleep in children with functional dyspepsia receiving melatonin.

NCT ID: NCT04683926 Completed - Pain Clinical Trials

A Randomized Study Investigating Oral Desmetramadol Dose Proportionality and Food Effect In Normal Human Subjects

Start date: January 8, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to investigate in healthy human subjects how much desmetramadol (Omnitram) gets in the blood after different oral doses are taken with or without food.

NCT ID: NCT04683900 Completed - Parkinson Disease Clinical Trials

Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial

MEDI-PD
Start date: February 8, 2021
Phase: N/A
Study type: Interventional

This is a 10-week randomized, controlled study to investigate the effect of a Mediterranean diet intervention on gastrointestinal function in Parkinson's disease. After a 2-week run-in period, participants will be instructed to receive standard of care for constipation or receive standard of care + follow a Mediterranean diet for 8 weeks and answer daily and weekly questionnaires. Nutritional and neurological evaluations and stool samples will be collected at 0, 4 and 8 weeks.

NCT ID: NCT04683874 Completed - Dental Bonding Clinical Trials

Transfer Accuracy of 3D-printed Indirect Bonding Trays

Start date: August 25, 2020
Phase: N/A
Study type: Interventional

This study evaluates the transfer accuracy of 3D-printed trays for indirect bonding of orthodontic brackets in vivo. Accurate placement of orthodontic brackets at the beginning of treatment improves treatment efficiency and shortens treatment time. Indirect bonding is a method of placing orthodontic brackets on a plaster or digital model of the dentition, followed by the transfer of these brackets to the patients' teeth using a transfer tray. Various indirect bonding methods have been developed with the aim of improved bracket positioning and reduced chair time. The success of these methods ultimately depends on how reliably the precise positioning of the brackets on the model can be transferred to the patient's teeth.

NCT ID: NCT04683731 Completed - Clinical trials for Cancer Screening Tests

Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening

Start date: January 19, 2021
Phase: N/A
Study type: Interventional

Precision prevention holds great promise for colorectal cancer (CRC) screening but has not been adequately explored. A patient's chance of having an advanced colorectal neoplasm (ACN), i.e. a cancer or precancerous polyp in the colon, significantly affects the comparative effectiveness of approved tests. Giving patients a decision aid with information about their risk for ACN, and giving their providers similar information, could help patients and providers decide if colonoscopy or a non-invasive test (such as the fecal immunochemical test) is more appropriate. This could improve decision making and increase uptake of CRC screening, which are the investigative team's long-term goals.

NCT ID: NCT04683640 Completed - Chronic Pain Clinical Trials

Latent Aging Mechanisms in Pain and Sleep

LAMPS
Start date: April 2, 2021
Phase: Phase 2
Study type: Interventional

Chronic pain is a serious public health problem in older adults depending on the pain condition, and the capacity to sleep properly changes with age. Given the potential mechanistic role of GABA (gamma-aminobutyric acid) in both conditions, based on our preliminary data, this proposal will determine the effect of oral GABA administration in sleep quality and pain in older adults with chronic pain and sleep disorders as well as to characterize the potential neurobiological mechanisms involved in both illnesses.

NCT ID: NCT04683627 Completed - Clinical trials for Osteoarthritis Pain of the Knee

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Start date: December 29, 2020
Phase: Phase 3
Study type: Interventional

A 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 study to Evaluate the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) Pain of the Knee

NCT ID: NCT04683471 Completed - Clinical trials for Spinal Cord Diseases

Pilot Trial of a System for Motor Function Recovery

Start date: November 30, 2020
Phase: N/A
Study type: Interventional

This is a multi-center, prospective, blinded, pilot feasibility study to evaluate improvement in sensory and motor function with sham.

NCT ID: NCT04683354 Completed - Solid Tumor, Adult Clinical Trials

Study of HL-085 in Patients With Advanced Solid Tumor Tumors

Start date: December 23, 2020
Phase: Phase 1
Study type: Interventional

The investigational product (IP) HL-085 is an adenosine triphosphate-noncompetitive mitogen activated protein kinase (MEK) inhibitor with a strong selective anti-tumor activity, with a much lower dose than selumetinib. It has been shown strong anti-tumor activities in preclinical studies to treat solid tumors, e.g., melanoma, non-small cell lung cancer, colon cancer and other malignancies with RAF and RAS mutations. Kechow has completed phase I dose escalation study to test HL-085 in patients with advanced NRAS mutated melanoma in China. The tested doses were 0.5 mg, 1mg, 2mg, 3mg, 4mg, 6mg, 9mg, 12mg, 15mg and 18mg BID oral administration and there was no dose-limiting toxicity (DLT) identified. All patients tolerated the study drug reasonably well. This study is a Phase I, open-label, dose escalation study to evaluate tolerability, safety, pharmacokinetic (PK) and preliminary antitumor activities of HL-085 in US patients with advanced solid tumors. The objective of the dose escalation is to evaluate safety and tolerability of selected TID and BID dose regimens in US patient population with advanced solid tumor and establish the Recommended Phase 2 Dose (RP2D). The starting dose for this trial is 12 mg daily oral administration. Three selected daily doses - 12 mg (4mg TID, 6mg BID), 18 mg (6mg TID, 9 mg BID), and 24 mg (8 mg TID, 12 mg BID) will be tested in this study to assess safety and tolerability of HL-085 at the 3 selected dose levels in US patient population with advanced solid tumors.